LRLudovic Reveiz

Ludovic Reveiz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ludovic Reveiz has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 July 2011
      • Vol. 30  (1) , 87-96

    Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency.

    by Karmela Krleža-Jeriç, Trudo Lemmens, Ludovic Reveiz, Luis Gabriel Cuervo, Lisa Anne Bero

    The objective of this article is to propose a roadmap toward transparency of clinical trials in the Americas by their prospective registration and results disclosure. This will broaden access to more complete and accurate data and facilitate evidence-informed decision-making and participation in research. Consequently, it should have a positive impact on people's health and should promote trust in health research. Existing initiatives were identified, registration of trials was analyzed following the World Health Organization (WHO) standards on trial registration, and a roadmap is proposed to address the gaps in advancing transparency. The analysis shows that, in spite of numerous regional and country initiatives, clinical trials taking place in nonEnglish-speaking parts of the Americas are underregistered. A roadmap is proposed to enhance research governance and good research practice by improving the transparency of clinical trials. The proposed roadmap includes strategies for implementing WHO international standards for trial registration, for developing international standards of public disclosure of trial results, and for a potential role of the Pan American Health Organization.


  • Chemotherapy for brain metastases from small cell lung cancer

    by Ludovic Reveiz, Mauricio Cuello, Santiago Viteri, Esther Carrasco, Andrés F Cardona


  • Open Access

    Do trialists endorse clinical trial registration? Survey of a Pubmed sample

    by Ludovic Reveiz, Karmela Krleža-Jerić, An-Wen Chan, Sylvia De Aguiar

    Despite intense interest in trial registration, there is a wide gap between theoretical postulates on trial registration and its implementation worldwide.


  • Enemas during labour

    by Ludovic Reveiz, Hernando G Gaitán, Luis Gabriel Cuervo

    The use of enemas during labour usually reflects the preference of the attending healthcare provider. However, enemas may cause discomfort for women and increase the costs of delivery. To assess the effects of enemas applied during the first stage of labour on infection rates in mothers and newborns, duration of labour, perineal wound dehiscence in the mother, perineal pain and faecal soiling. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (March 2007), PubMed (1966 to December 2006), the Cochrane Central Register of Controlled Trials and Database of Abstracts of Reviews of Effectiveness (The Cochrane Library 2006, Issue 4), clinical trials registers (December 2006) and reference lists of articles. Randomized controlled trials (RCTs) in which an enema was administered during the first stage of labour and which included assessment of possible neonatal or puerperal morbidity or mortality. Two review authors assessed studies for inclusion independently. Three RCTs (1765 women) met the inclusion criteria. Meta-analysis revealed no significant differences for infection rates in puerperal women (2 RCTs; 594 women; relative risk (RR) 0.66, 95% CI 0.42 to 1.04) or newborn children (1 RCT; 370 newborns; RR 1.12, 95% CI 0.76 to 1.67) after one month of follow up. No significant differences were found in the incidence of lower or upper respiratory tract infections. One trial described labour to be significantly shorter with enema versus no enema (1 RCT, 1027 women; 409.4 minutes versus 459.8 minutes; weighted mean difference (WMD) -50,40 CI 95% -75.68 to -25.12; P < 0.001), but another, adjusted for parity, did not confirm this (median 515 minutes with enemas versus 585 minutes without enemas, P = 0.24). Two trials found no significant differences in neonatal umbilical infection (2 RCTs; 592 newborns; RR 3.16 95% CI 0.50 to 19.82). The one trial that researched women's views found no significant differences in satisfaction between groups. The evidence provided by the three included RCTs shows that enemas do not have a significant effect on infection rates such as perineal wound infection or other neonatal infections and women's satisfaction. This evidence does not support the routine use of enemas during labour; therefore, such practice should be discouraged.


  • Antibiotics for acute laryngitis in adults

    by Ludovic Reveiz, Andrés Felipe Cardona, Edgar Guillermo Ospina

    Acute laryngitis is a common illness worldwide. Diagnosis is often made by case history alone and treatment is often directed towards controlling symptoms. The aim of this review was to assess the effectiveness of different antibiotic therapies in adults suffering acute laryngitis. A secondary objective was to report the rates of adverse events associated with these treatments. We systematically screened the following electronic databases: the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2006); MEDLINE (January 1966 to December Week 2 2006); and EMBASE (1974 to June 2006), LILACS (from 1982 to December 2006 ) and BIOSIS (1980 to June 2002). Other strategies included hand searching relevant journals, searching ongoing trial databases and general databases such as Google scholar. Randomized controlled trials comparing any antibiotic therapy with placebo in acute laryngitis. The main outcome measurement was objective voice scores. Data were independently extracted by two review authors and then descriptively synthesized. Only two trials met study inclusion criteria after extensive literature searches. One hundred participants were randomly selected to receive either penicillin V (800 mg twice a day for five days), or an identical placebo, in a study of penicillin V in acute laryngitis in adults. A tape recording of each patient reading a standardized text was obtained during the first visit, subsequently during re-examination after one and two weeks, and at follow up after two to six months. No significant differences were found between the groups. The trial also measured symptoms reported by participants and found no significant differences. The second trial investigated erythromycin for treating acute laryngitis in 106 adults. The mean objective voice scores measured at the first visit, at re-examination after one and two weeks, and at follow up after two to six months did not significantly differ between control and intervention groups. At one week there were significant beneficial differences in the severity of reported vocal symptoms as judged by the participants (P = 0.042). Comparing the erythromycin and placebo groups on subjective voice scores the a priori relative risk (RR) was 0.7 (95% confidence interval (CI) 0.51 to 0.96, P = 0.034) and the number needed to treat (NNT) was 4.5. Antibiotics appear to have no benefit in treating acute laryngitis. Erythromycin could reduce voice disturbance at one week and cough at two weeks when measured subjectively. We consider that these outcomes are not relevant in clinical practice. The implications for practice are that prescribing antibiotics should not be done in the first instance as they will not objectively improve symptoms.


  • An e-mail survey identified unpublished studies for systematic reviews

    by Ludovic Reveiz, Andres Felipe Cardona, Edgar Guillermo Ospina, Sylvia de Agular


  • The Latin American Ongoing Clinical Trial Register (LATINREC)

    by Ludovic Reveiz, Martha B. Delgado, Gerard Urrutia, Zulma Ortiz, Marcelo Garcia Dieguez, Arturo Martí-Carvajal, Erwin Calgua, Armando Vieyra, Agustín Ciapponi, Ricardo Hidalgo, et al.


  • How should we rate research?: Cost of research should be disclosed publicly

    by Ludovic Reveiz

    Footnotes Competing interests None declared.


  • If it doesn't work, stop it

    by Ludovic Reveiz

    Footnotes Competing interests None declared.

  • Antibiotics for acute laryngitis in adults

    by Edgar Guillermo Ospina, Ludovic Reveiz, A F Cardona, Carlos Eduardo Granados, J V Osorio, Andrés Felipe Cardona Zorrilla